Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Humanm Antibodys:ABGX,MEDX, CAT , Morphosys.... -- Ignore unavailable to you. Want to Upgrade?

To: Mel Spivak who wrote (4)	1/26/2000 11:10:00 AM
From: Jongmans	Read Replies (1) \| Respond to of 23

Cambridge Antibody Technology and MorphoSys continue their strong uptrend. martin

To: Mel Spivak who wrote (4)	3/10/2000 8:03:00 AM
From: Mel Spivak	Respond to of 23

MEDX in a new collaboration w REGN: Medarex, Regeneron to co-develop, market new drugs PRINCETON, N.J., March 10 (Reuters) - Medarex Inc. (NasdaqNM:MEDX - news) and Regeneron Pharmaceuticals Inc. (NasdaqNM:REGN - news) have formed an alliance to develop and market drugs based on antibodies, the natural disease fighters made by the body's immune system, Medarex said on Friday. The companies have selected more than 20 initial targets, including growth factors, and anticipate adding more targets in the future. The companies will share preclinical and clinical responsibilities and will jointly market any drugs that result from the strategic alliance, Medarex said in a statement. Further details of the collaboration were not immediately available. Medarex uses a technology that produces large quantities of an antibody that binds very selectively with a foreign invader. Regeneron has developed potential new treatments for some of the most serious and widespread disease and conditions, including cancer, asthma, arthritis and vascular disease. Medarex shares closed on Thursday at 166-41/32. Regeneron closed at 41-9/16